
BONESUPPORT (Q3 Review) - Still just getting started

Redeye returns with a more in-depth take on the Q3 report. The miss on sales and EBIT increased the market's scepticism, but we believe the coming quarters will reinforce the market's understanding of BONESUPPORT's profitable, high-growth sales trajectory.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BONESUPPORT (Q3 Review) - Still just getting started